6-(Methylthio)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one, 95+%, 250mg

(S)-2-Propylpiperidine hydrochloride, 97.0%, 50mg

6-(2,3,3-Trimethyl-3H-indol-1-ium-1-yl)hexanoate hydrobromide, 95%, 250mg

1-(2-ethoxyethyl)-1H-pyrazol-4-amine, 95.0%, 2g

tert-Butyl (R)-2-(tert-butyl)piperazine-1-carboxylate hydrochloride, 95%, 1g

1-Bromonaphthalene>95.0%(GC)100g

METHYL 4-BROMO-2-OXO-1,3-DIHYDROINDOLE-6-CARBOXYLATE, 95.0%, 25g

Methyl 5-amino-4-methylpicolinate, 95.0%, 1g

2-[(Tetrahydro-1,1-dioxido-3-thienyl)thio]acetic acid, 97%, 250mg

N-BOC-4-NITROBENZENESULFONAMIDE, 90.0%, 1g

2-Hexyl-malonic acid, 98.0%, 250mg

Methyl 2-[4-chloro-3-(trifluoromethyl)phenoxy]-acetate, 1g

Microliter syringe GASTIGHT® series 1700 Point type 2, 100 µl, 1710 RN, 1 piece